Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin + Nivolumab + Paclitaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Nivolumab | Opdivo | MDX-1106|BMS-936558 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Opdivo (nivolumab) is an antibody that targets PD-1 (PDCD1), which results in increased T-cell activation and enhanced anti-tumor immune response (PMID: 28891423). Opdivo (nivolumab) is FDA approved for use as a monotherapy in patients with non-small cell lung cancer (NSCLC) progressed on prior therapies, Hodgkin's lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma (UC) , esophageal squamous cell carcinoma, resected esophageal or gastroesophageal junction (GEJ) cancer, as a monotherapy or in combination with Yervoy (ipilimumab) for melanoma, renal cell carcinoma (RCC), microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (including patients 12 years or older), and hepatocellular carcinoma, in combination with Yervoy (ipilimumab) as first-line therapy for PD-L1-positive (>=1%) metastatic NSCLC without EGFR or ALK alterations, with Yervoy (ipilimumab) and platinum-based chemotherapy as first-line therapy for metastatic or recurrent NSCLC without EGFR or ALK alterations, with platinum doublet chemotherapy as neoadjuvant treatment for patients with resectable NSCLC, with Cabometyx (cabozantinib) for advanced RCC, with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, GEJ cancer, and esophageal adenocarcinoma, and with cisplatin and gemcitabine as first-line treatment for unresectable or metastatic UC (FDA.gov). |
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06094296 | Phase II | Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Completed | USA | AUS | 0 |
NCT03342911 | Phase II | Carboplatin + Nivolumab + Paclitaxel | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | Completed | USA | 0 |
NCT03245892 | Phase I | Carboplatin + Nivolumab + Paclitaxel | A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT03107182 | Phase II | Dexamethasone + Diphenhydramine + Famotidine + Fluorouracil + Hydroxyurea + Paclitaxel Carboplatin + Nab-paclitaxel + Nivolumab Cisplatin Carboplatin + Nivolumab + Paclitaxel Nivolumab | Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer (OPTIMA-II) | Completed | USA | 0 |
NCT05583188 | FDA approved | Cisplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Gemcitabine + Nivolumab Carboplatin Cisplatin + Nivolumab + Paclitaxel Carboplatin + Docetaxel + Nivolumab Cisplatin Carboplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Paclitaxel Pemetrexed Disodium Vinorelbine Gemcitabine Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium | Neoadjuvant Aliya PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC (VIGOR) | Terminated | USA | 0 |
NCT06275360 | Phase II | Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel | Repositioning Immunotherapy in VetArans With Lung Cancer (RIVAL) | Recruiting | USA | 0 |
NCT06003075 | Phase II | Carboplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab Carboplatin + Gemcitabine + Nivolumab | Induction Chemo-Nivo in Unresectable Stage III NSCLC | Terminated | USA | 0 |
NCT04331067 | Phase Ib/II | Cabiralizumab + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Paclitaxel | Cabiralizumab in Combination With Nivolumab and Neoadjuvant Chemotherapy in Patients With Localized Triple-negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03823625 | Phase II | Ipilimumab + Nivolumab Carboplatin + Gemcitabine + Nivolumab Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab | An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) (SQUINT) | Unknown status | ITA | 0 |
NCT05500092 | Phase II | Carboplatin + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel Carboplatin + Docetaxel + Nivolumab Carboplatin + Nivolumab + Paclitaxel Cisplatin + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Gemcitabine + Nivolumab Cisplatin + Docetaxel + Nivolumab | An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer (CA209-6K6) | Recruiting | USA | 0 |
NCT03044613 | Phase I | Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Paclitaxel | Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer | Active, not recruiting | USA | 0 |
NCT03944915 | Phase II | Carboplatin + Nivolumab + Paclitaxel Cisplatin + Filgrastim + Fluorouracil + Hydroxyurea + Paclitaxel | De-Escalation Therapy for Human Papillomavirus Negative Disease (DEPEND) | Recruiting | USA | 0 |
NCT03829722 | Phase II | Carboplatin + Nivolumab + Paclitaxel | Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer | Completed | USA | 0 |
NCT06667154 | Phase II | Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel | Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy | Recruiting | BRA | 0 |
NCT05684276 | Phase II | Carboplatin + Nivolumab + Paclitaxel | DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors (DUMAS) | Recruiting | ESP | 0 |
NCT04564157 | Phase III | Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel | New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT) | Active, not recruiting | ESP | 0 |
NCT03604991 | Phase II | Carboplatin + Paclitaxel Nivolumab Carboplatin + Nivolumab + Paclitaxel Ipilimumab + Nivolumab | Carboplatin, Paclitaxel and Radiation Therapy With or Without Nivolumab and Ipilimumab in Treating Participants With Esophageal and Gastroesophageal Junction Adenocarcinoma | Suspended | USA | 0 |
NCT04444921 | Phase III | Carboplatin + Paclitaxel Carboplatin + Nivolumab + Paclitaxel | Testing the Addition of Nivolumab to Chemotherapy for Patients With Metastatic Anal Cancer | Active, not recruiting | USA | 0 |
NCT03838159 | Phase II | Carboplatin + Nivolumab + Paclitaxel Carboplatin + Paclitaxel | NADIM II: Neo-Adjuvant Immunotherapy (NADIMII) | Active, not recruiting | ESP | 0 |